Key result
Intravenous aprindine terminated atrio-ventricular reentrant tachycardia in all 8 cases where it was sustained, and prevented its induction in 5 out of 10 cases in patients with WPW syndrome.
Why the study?
Does intravenous aprindine terminate and prevent the induction of atrio-ventricular reentrant tachycardia in patients with WPW syndrome?
Observational (n=11)
No
Does intravenous aprindine terminate and prevent the induction of atrio-ventricular reentrant tachycardia in patients with WPW syndrome?
Intravenous aprindine is highly effective in acutely terminating and preventing the induction of AVRT in patients with WPW syndrome, primarily by blocking retrograde conduction over the accessory pathway.
Answers are grounded in this paper and cite their sources.
Aprindine may aid acute AVRT termination in WPW; hypothesis-generating case data leave efficacy unconfirmed.
[in Japanese]
No takes yet. Share an insight, caveat, or question.
Hirao et al. (1984) conducted an observational in Wolff-Parkinson-White (WPW) syndrome with Atrio-Ventricular Reentrant Tachycardia (AVRT) (n=11). Aprindine hydrochloride vs. Baseline (pre-administration) was evaluated on Termination of sustained atrio-ventricular reentrant tachycardia. Intravenous aprindine terminated atrio-ventricular reentrant tachycardia in all 8 cases where it was sustained, and prevented its induction in 5 out of 10 cases in patients with WPW syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: